# Inhibition of VE-PTP rejuvenates Schlemm’s canal in aged mice and acts via Tie2

**Authors:** Sarthak Mishra, Ute Ipe, Astrid F. Nottebaum, Kevin G. Peters, Dietmar Vestweber

PMC · DOI: 10.1371/journal.pone.0323615 · PLOS One · 2025-05-16

## TL;DR

This study shows that inhibiting VE-PTP can rejuvenate Schlemm’s canal in aged mice, reducing eye pressure through Tie2, offering a potential treatment for glaucoma.

## Contribution

The study demonstrates that VE-PTP inhibition rejuvenates Schlemm’s canal in aged mice in a Tie2-dependent manner.

## Key findings

- Pharmacologic inhibition of VE-PTP with AKB9778 increased Schlemm’s canal area only in mice expressing Tie2.
- AKB9778 improved Schlemm’s canal function and lowered intraocular pressure in aged mice.
- VE-cadherin-Y685F mutation had no effect on Schlemm’s canal area or AKB9778’s effects.

## Abstract

Glaucoma is the leading cause of irreversible blindness worldwide and is associated with high intraocular pressure (IOP). Schlemm’s canal (SC), a hybrid vessel present in the anterior part of the eye, is known to control IOP by draining aqueous humor into the systemic circulation. Formation and function of SC is supported by the tyrosine kinase receptor Tie2. Likewise, inhibition of the vascular endothelial protein tyrosine phosphatase (VE-PTP), which associates with Tie2 has similar effects. However, VE-PTP also targets VE-cadherin and several other substrates. Here, we analyzed whether Tie2 is indeed the major substrate which is responsible for the role of VE-PTP in SC function. In addition, we analyzed the function of VE-PTP in SC of the aged eye in mice.

We tested the effects of the VE-PTP inhibitor AKB9778 and of VE-PTP gene inactivation on SC area and IOP in WT and in Tie2iLEC/SC-KO and VE-cadherin-Y685F mutant mice.

Pharmacologic inhibition of VE-PTP with AKB9778 increased SC area only in mice expressing Tie2. The VE-cadherin-Y685F mutation had neither an effect on SC area nor on the effects of AKB9778 on SC formation. Induced VE-PTP gene inactivation in adult mice had similar effects as AKB9778. Furthermore, we could show that AKB9778 improved SC function in aged mice as judged by increasing SC area and lowering of IOP.

Interference with VE-PTP function improves SC function in a strictly Tie2 dependent way and pharmacologic inhibition of VE-PTP with AKB9778 is a promising approach for improving SC function in the aged eye.

## Linked entities

- **Genes:** TEK (TEK receptor tyrosine kinase) [NCBI Gene 7010], cdh5 (cadherin 5) [NCBI Gene 100488458]
- **Proteins:** PTPRB (protein tyrosine phosphatase receptor type B)
- **Chemicals:** AKB9778 (PubChem CID 46700782)
- **Diseases:** glaucoma (MONDO:0005041)
- **Species:** Mus musculus (taxon 10090)

## Full-text entities

- **Genes:** Angpt2 (angiopoietin 2) [NCBI Gene 11601] {aka Agpt2, Ang-2, Ang2}, Mki67 (antigen identified by monoclonal antibody Ki 67) [NCBI Gene 17345] {aka D630048A14Rik, Ki-67, Ki67}, Prox1 (prospero homeobox 1) [NCBI Gene 19130] {aka A230003G05Rik, PROX-1}, Angpt1 (angiopoietin 1) [NCBI Gene 11600] {aka 1110046O21Rik, Ang-1, Ang1}, Tek (TEK receptor tyrosine kinase) [NCBI Gene 21687] {aka Cd202b, Hyk, STK1, Tie-2, Tie2}, Mapk3 (mitogen-activated protein kinase 3) [NCBI Gene 26417] {aka Erk-1, Erk1, Ert2, Esrk1, Mnk1, Mtap2k}, Ptprb (protein tyrosine phosphatase receptor type B) [NCBI Gene 19263] {aka 3230402H02Rik, C130094E24, Ptpz, Rptpb, VE-PTP, Veptp}, Casp3 (caspase 3) [NCBI Gene 12367] {aka A830040C14Rik, AC-3, CASP-3, CC3, CPP-32, CPP32}, Cdh5 (cadherin 5) [NCBI Gene 12562] {aka 7B4, Cd144, VE-Cad, VECD, VEcad, Vec}, Pdgfb (platelet derived growth factor subunit B) [NCBI Gene 18591] {aka PDGF-2, PDGF-B, Sis, c-sis}, Pecam1 (platelet/endothelial cell adhesion molecule 1) [NCBI Gene 18613] {aka Cd31, PECAM-1, Pecam}, Dep1 (diabetic embryopathy 1) [NCBI Gene 170624]
- **Diseases:** Glaucoma (MESH:D005901), age related open-angle glaucoma (MESH:D005902), ocular hypertension (MESH:D009798), vision loss (MESH:D014786), PCG (MESH:C565547), diabetic retinopathy (MESH:D003930), glaucomatous eyes (MESH:D005134), vascular defects (MESH:D057772), blindness (MESH:D001766), Dysfunction in SC (MESH:D056735)
- **Chemicals:** phosphotyrosine (MESH:D019000), Tamoxifen (MESH:D013629), Isoflurane (MESH:D007530), NP-40 (MESH:C010615), xylazine (MESH:D014991), ethanol (MESH:D000431), Triton X-100 (MESH:D017830), peanut oil (MESH:D000074241), Alexa-647 (MESH:C569686), PBS (MESH:D007854), tyrosine (MESH:D014443), AKB 9778 (MESH:C000598564), Alexa-568 (MESH:C000607448), ABTAA (-), CO2 (MESH:D002245), latanoprost (MESH:D000077338)
- **Species:** Oryctolagus cuniculus (domestic rabbit, species) [taxon 9986], Rattus norvegicus (brown rat, species) [taxon 10116], Mus musculus (house mouse, species) [taxon 10090], Homo sapiens (human, species) [taxon 9606]
- **Mutations:** Tyr685, Y685F
- **Cell lines:** C57BL/6 — Mus musculus (Mouse), Transformed cell line (CVCL_C0MU)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12084045/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12084045/full.md

## References

52 references — full list in the complete paper: https://tomesphere.com/paper/PMC12084045/full.md

---
Source: https://tomesphere.com/paper/PMC12084045